143142-90-9

Basic information

• Product Name: R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97
• Synonyms: R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97;(2R)-2-(Trifluoromethyl)oxirane (ee);(2R)-(+)-3,3,3-Trifluoro-1,2-propenoxide;(2R)-2-(Trifluoromethyl)oxirane, (2R)-1,2-Epoxy-3,3,3-trifluoropropane;(2R)-2-(trifluoromethyl)oxirane
• CAS NO: 143142-90-9
• Molecular Formula: C₃H₃F₃O
• Molecular Weight: 112.0505296
• Mol File: 143142-90-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 25-32 °C
• Flash Point: -15 °F
• Appearance: white crystal powder
• Density: 1.294 g/mL at 25 °C
• Vapor Pressure: 560mmHg at 25°C
• Refractive Index: n20/D <1.300
• Storage Temp.: 2-8°C
• CAS DataBase Reference: R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97(CAS DataBase Reference)
• NIST Chemistry Reference: R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97(143142-90-9)
• EPA Substance Registry System: R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97(143142-90-9)

Safety Data

• Hazard Codes: F+
• Statements: 12
• Safety Statements: 3
• RIDADR: UN 1993 3/PG 1
• WGK Germany: 3
• Hazardous Substances Data: 143142-90-9(Hazardous Substances Data)

Usage

Description

R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97, also known as (R)-(+)-3,3,3-Trifluoro-1,2-epoxypropane, is a chemical compound with a trifluoromethyl group and an epoxide ring. It is a versatile building block in the synthesis of various pharmaceutical compounds and has potential applications in the development of new drugs.

Uses

Used in Pharmaceutical Industry:
R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97 is used as a substrate for the synthesis of substituted trifluoro amino propanols, which are potent inhibitors of cholesteryl ester transfer protein. These inhibitors play a crucial role in managing cholesterol levels and can be used in the treatment of cardiovascular diseases.
Used in Chiral Synthesis:
R-(+)-2-TRIFLUOROMETHYLOXIRANE, 97 is used as a starting material for the preparation of (2R) Trifluoro-(methoxybenzyloxy)-propanol (chiral glycol) by reacting with 4-methoxybenzyl alcohol in the presence of NaH. This chiral glycol intermediate is further utilized in the synthesis of trifluoromethyl glycol carbamates, which have potential as monoacylglycerol lipase (MAGL) inhibitors. MAGL inhibitors can be used in the treatment of various conditions, including pain, inflammation, and neurodegenerative diseases.

InChI:InChI=1/C3H3F3O/c4-3(5,6)2-1-7-2/h2H,1H2/t2-/m1/s1

Upstream product

• 431-35-6 3-bromo-1,1,1-trifluoroacetone 
• 359-41-1 1,1,1-trifluoro-2,3-epoxypropane 
• 137429-44-8 3-bromo-1,1,1-trifluoropropan-2-ol 

Downstream Products

• 1615720-80-3 (R)-N-(6-(4-(4-fluorophenyl)-1-(1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl)-1H-imidazol-5-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide 
• 1615721-10-2 (R)-2-fluoro-N-(6-(4-(4-fluorophenyl)-1-(1-(3,3,3-trifluoro-2-hydroxypropyl)piperidin-4-yl)-1H-imidazol-5-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide 
• 374-01-6 (R)-1,1,1-trifluoropropanol 
• 1204344-00-2 (2R)-1,1,1-trifluoro-3-[(4-methoxybenzyl)oxy]propan-2-ol 
• 1616234-53-7 (R)-2-fluoro-N-(6-(3-(4-fluorophenyl)-1-methyl-5-(4-(3,3,3-trifluoro-2-hydroxypropyl)piperazin-1-yl)-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide 
• 1212136-13-4 (R)-3-(benzylamino)-1,1,1-trifluoropropan-2-ol 
• 1426696-46-9 (2R)-3-(3-{3-[1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-methoxy-6-methylphenyl}azetidin-1-yl)-1,1,1-trifluoropropan-2-ol 
• 1425037-11-1 (R)-3-((S)-4-(3-trifluoromethoxybenzyl)-2-phenyl-3,4-dihydroquinoxalin-1(2H)-yl)-1,1,1-trifluoropropan-2-ol 
• 1425037-09-7 (R)-3-((R)-4-(3-trifluoromethoxybenzyl)-2-phenyl-3,4-dihydroquinoxalin-1(2H)-yl)-1,1,1-trifluoropropan-2-ol 
• 1425037-41-7 (R)-3-[(2-aminophenyl)amino]-1,1,1-trifluoropropan-2-ol 
• 1338560-79-4 C₁₁H₁₁F₃O₃S 
• 1032187-44-2 (R)-1,1,1-trifluoro-3-((S)-2-(3-fluoro-5-(trifluoromethyl)phenyl)-2-(5-fluoropyridin-2-yl)-3-phenylpropylamino)propan-2-ol 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS

The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.

Method for Industrial Production of Optically Active Fluoroalkyl Ethylene Oxide

It is possible to produce an optically active fluoroalkyl chloromethyl alcohol with a high optical purity and a good yield by treating a fluoroalkyl chloromethyl ketone with a microorganism having an activity for asymmetrically reducing the ketone or an enzyme having the activity. Then, it is possible to obtain a fluoroalkyl ethylene oxide by treating the alcohol with a base. Industrial implementation of the production method of the present invention is easy.